High-dose rate brachytherapy for vaginal cancer
Author Information
Author(s): Sushil Beriwal, Dwight E. Heron, Robert Mogus, Robert P. Edwards, Joseph L. Kelley, Paniti Sukumvanich
Primary Institution: University of Pittsburgh Cancer Institute
Hypothesis
The study aims to evaluate the efficacy of HDR brachytherapy for primary or recurrent vaginal cancer.
Conclusion
HDR brachytherapy is effective for treating primary or recurrent vaginal cancer, especially in patients without prior radiation therapy.
Supporting Evidence
- Complete response was achieved in 94% of patients.
- The 2-year local control rate was 88%.
- Patients with primary disease had a 100% local control rate.
- Patients with recurrence without prior radiation also had a 100% local control rate.
- Patients with recurrence and prior radiation had a lower local control rate of 67%.
- Two patients experienced late grade 3 or higher morbidity.
Takeaway
Doctors used a special type of radiation treatment to help patients with vaginal cancer, and it worked really well for most of them.
Methodology
18 patients were treated with HDR brachytherapy between 2000 and 2006, with a median follow-up of 18 months.
Limitations
The study has a small sample size and limited follow-up, making it difficult to generalize the results.
Participant Demographics
Median age of participants was 69 years, with a mix of primary and recurrent vaginal cancer cases.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website